The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma.

ABSTRACT: Despite recent advancements in therapy, melanoma remains a highly lethal skin cancer. A better understanding of the genetic and epigenetic changes responsible for melanoma formation and progression could result in the development of more effective treatments. Advanced melanomas are known to exhibit widespread promoter region CpG island methylation leading to the inactivation of key tumor suppressor genes. Meta-analyses of relevant microarray data sets revealed the hematopoietic stem cell regulator gene latexin (LXN) to be commonly downregulated in approximately 50% of melanomas. The CpG island in the promoter region of LXN was almost universally hypermethylated in melanoma cell lines and tumors, and treatment of the cell lines with the demethylating drug 5-aza-2'-deoxycytidine resulted in

SUBMITTER: Muthusamy V 

PROVIDER: S-EPMC3683103 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature